Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

GE HealthCare aims to advance a new era in theranostics with StarGuide™ GX 4D SPECT ...

8 September 2026 · By · Wire by Fusion42

Published

8 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at gehealthcare.com →

◆ Verified

Fusion42 · 8 September 2026 · Fusion42 review

GE HealthCare has submitted a 510(k) application to the U.S. FDA for its StarGuide GX 4D SPECT/CT system, aiming to advance theranostics by integrating advanced imaging technologies for precision medicine.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You face a narrow regulatory opening in the U.S. medtech market as GE HealthCare moves toward FDA clearance for theranostic imaging. Prepare your product strategy to engage clinical partners eager for advanced SPECT/CT solutions.

◆ Coverage

1 source · 8 Sep 2026

◆ Related on Wire

◆ Topics

Medtechtheranosticsmedical-imagingfda-approvalhealthcare-technology